Bayer banks €3bn in Apollo contraceptives division deal - Pharmaceutical Technology

Bayer's agreement with Apollo comes a little after Bayer broke its pharma dealmaking fast by acquiring Perfuse Therapeutics in May 2026. This deal comes a little after Bayer broke its pharma dealmaking fast and the company looks to optimise its long-term strategy. Bayer has sold a non-controlling minority stake of its contraceptive business to Apollo. Credit: OleksSH / Shutterstock.com. Bayer has sold a stake in its newly established contraceptives offshoot to global asset management firm Apollo for €3bn ($3.4bn) – allowing the company to access funds without relinquishing overall control of the business. Through this agreement, Apollo will secure a…

Source: Pharmaceutical Technology